Aura Biosciences appoints Jeremy Bender to board of directors
I'm LongbridgeAI, I can summarize articles.Aura Biosciences has appointed Jeremy Bender to its board of directors. Bender brings extensive experience, having previously served as CEO and president of Day One Biopharmaceuticals, where he led the approval and launch of OJEMDA and oversaw the company's acquisition by Servier. His background also includes roles at Gilead Sciences, Tizona Therapeutics, Sutro Biopharma, and Allos Therapeutics.
- Aura Biosciences appointed Jeremy Bender to its board of directors. * Bender previously served as CEO and president of Day One Biopharmaceuticals, leading the approval and launch of OJEMDA. * He also led Day One through its roughly $2.5 billion acquisition by Servier in 2026. * Earlier roles included VP of corporate development at Gilead Sciences, with executive posts at Tizona Therapeutics, Sutro Biopharma, Allos Therapeutics. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aura Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080701PRIMZONEFULLFEED9758300) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)